PREVIOUS ISSUE NEXT ISSUE
May 2016 MHE0516_CV1.jpg
Health execs: Advice I would give my younger selfLooking back on your career, what advice do you wish you had starting out? Here’s what our editorial advisory board said.
What’s behind the drop in hospital-acquired conditions?A report from the Department of Health and Human Services indicates positive momentum in efforts to combat hospital-acquired conditions, but experts say more can be done.
Driving down heart disease costs: Tips for plans, providersHeart disease takes a heavy toll on the healthcare system, but promising new treatments are emerging
Top 3 cardiovascular patient compliance challengesStaying compliant with a prescribed treatment regimen gives cardiovascular disease patients the best chance of improving their heart health and reducing future incidences of cardiac events. Here’s how to get patients on board.
Impact of Medicare's expanded benzodiazepine coverageLike any medication, benzodiazepines should be used with caution. However, the tremendous expenditure for these medications—just a year after Medicare Part D extended its coverage to include them in 2012—has some wondering why so many of these drugs are being prescribed.
M&A outlook for payers and providersA glimpse into the present and future of healthcare industry mergers and acquisitions
Will wearables and healthcare ever sync?Though technology companies are continuing to innovate in the wearable field, healthcare organizations are slow to adapt.
Five strategies that drive higher value careDoug Chaet, senior vice president, Provider Networks and Value-Based Solutions at Independence Blue Cross, shares five strategies that can help providers succeed in value-based reimbursement models.
Pharma coupons: pros and consDrug coupons sound good on paper for both manufacturers who sell more products and for patients who pay less for a high-priced new product. But payers and pharmacy benefits managers are not impressed.
Telemonitoring of heart failure patients reduces readmissionsStudy demonstrates how new technology can drive higher value healthcare for heart failure patients.
Cardiovascular drugs: Current spending, future outlookCardiovascular drugs are among the most widely used, since their indications are far reaching and address conditions that are prevalent among a large population.
Policy vs. legal perspectives on healthcare price transparencyA recent Supreme Court decision shines the spotlight on the healthcare price transparency debate.
Blue Shield of California CEO shares ACO success secretsInsight from Paul Markovich, CEO, Blue Shield of California
Seven wearable devices health execs should watchSome of the newest wearable devices on the market look very different than the wristbands that launched the industry just a few years ago.
PREVIOUS ISSUE NEXT ISSUE